

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

PTO Form 1449

Attorney Docket  
056291-5202

Application No. 10/530,566

Applicants: Alan BARGE

PAGE 1 of 1

I. A. Filing Date: October 6, 2003

Group Art Unit: Unassigned

## U.S. PATENT DOCUMENTS

Initial	Document No.	Date	Name	Class	Sub-Class	Filing Date
/K.C./	1. US 6,423,753	July 23, 2002	Dougherty	514	719	January 5, 2000
/K.C./	2. US 20030055024	March 20, 2003	Davis	514	114	September 26, 2002
/K.C./	3. US 20030166617	September 4, 2003	Davis et al.	514	114	April 4, 2003

## FOREIGN PATENT DOCUMENTS

Document No.	Date	Country	Class	Sub-Class	Translation
/K.C./ 4. WO 99/02166	January 21, 1999	WIPO			
/K.C./ 5. WO 00/48591	August 24, 2000	WIPO			
/K.C./ 6. WO 01/32651	May 10, 2001	WIPO			
/K.C./ 7. WO 01/74360	October 11, 2001	WIPO			
/K.C./ 8. WO 01/74368	October 11, 2001	WIPO			
/K.C./ 9. WO 02/56692	July 25, 2002	WIPO			
/K.C./ 10. WO 03/088971	October 30, 2003	WIPO			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

/K.C./	11.	Blakey et al. (2002) "Antitumor Activity of the Novel Vascular Targeting Agent ZD6126 in a Panel of Tumor Models" Clin. Cancer Res. 8: 1974-1983
/K.C./	12.	Bruns et al. (2002) "Vascular-targeting activity of ZD6126 against primary pancreatic tumour growth and lymph node metastasis following orthotopic tumour cell injection in a nude mouse model" 14th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Abstract 118
/K.C./	13.	Chaplin et al. (2002) "The development of combretastatin A4 phosphate as a vascular targeting agent" Int J Radiat Oncol Biol Phys. 54(5): 1491-1496
/K.C./	14.	Davis et al. (2002) "ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature" Cancer Res. 62(24): 7247-7253
/K.C./	15.	Grosios et al. (2000) "Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma" Anticancer Res. 20: 229-233
/K.C./	16.	Horsman et al. (2000) "Combretastatins novel vascular targeting drugs for improving anti-cancer therapy" Advances in Experimental Medical Biology 476: 311-323
/K.C./	17.	Li et al. (2002) "Preclinical evaluation of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma" Acta Oncol. 41(1):91-97
/K.C./	18.	Siemann et al. (2002) "Enhancement of radiation therapy by the novel vascular targeting agent ZD6126" Int J Radiat Oncol Biol Phys. 53(1): 164-171
/K.C./	19.	Siemann et al. (2002) "Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy" Int J Cancer 99(1): 1-6
/K.C./	20.	Thorpe et al. (2003) "The First International Conference on Vascular Targeting: Meeting Overview" Cancer Res 63: 1144-1147

Examiner

/Kendra Carter/

Date Considered

02/18/2009

**Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.